Fleury SA operates within the Medical laboratories sector. In addition to historical fundamental analyses, the complete report available to purchase compares Fleury SA with three other pharmaceutical manufacturers in Latin America: Hypera SA (2019 sales of 3.29 billion Brazilian Reals [US$622.58 million] ), Genomma Lab Internacional Sab De Cv of MEXICO (12.71 billion Mexican Pesos [US$648.61 million] of which 100% was PC), and Diagnosticos Da America SA (4.36 billion Brazilian Reals [US$824.73 million] of which 100% was servi os auxiliares).

Sales Analysis. During the year ended December of 2019, sales at Fleury SA were 2.91 billion Brazilian Reals (US$548.95 million). This is an increase of 9.0% versus 2018, when the company's sales were 2.66 billion Brazilian Reals. This was the fifth consecutive year of sales increases at Fleury SA (and since 2014, sales have increased a total of 73%). Sales of Diagnostic Medicine saw an increase of 9.3% in 2019, from 2.23 billion Brazilian Reals to 2.44 billion Brazilian Reals.